Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death
Authors:
Open Access
- 19 September 2011
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 395
Abstract
To access the prognostic significance of HER-2 overexpression, the effect of trastuzumab and the cause of death in patients with brain metastases (BM) from breast cancer (BC).Keywords
This publication has 43 references indexed in Scilit:
- Preliminary Results of Whole Brain Radiotherapy With Concurrent Trastuzumab for Treatment of Brain Metastases in Breast Cancer PatientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patientsBritish Journal of Cancer, 2009
- Survival in patients with brain metastases from breast cancerCancer, 2008
- Defining prognosis for women with breast cancer and CNS metastases by HER2 statusAnnals of Oncology, 2008
- HER-2/neu expression in primary and metastatic breast cancerBreast Cancer Research and Treatment, 2008
- Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)Annals of Oncology, 2006
- Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinomaCancer, 2003
- Identification of prognostic factors in patients with brain metastases: a review of 1292 patientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999
- Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trialsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958